Global Rivastigmine Market Size, Share and Trends Analysis Report,By Disease Indication (Alzheimer Disease and Parkinson’s Disease), By Formulation ( Capsules and Transdermal Patches), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global rivastigmine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butyrylcholinesterase and acetylcholinesterase and it is a cholinergic agent that helps in the treatment of Alzheimer’s and Parkinson’s disease. The drug can be used in the form of transdermal patches, due to its small cell size. The considerable rise in the number of patients suffering from Alzheimer’sdisease and Parkinson’s disease across the globe along with the increase in the level of public awareness about diseases and their symptoms has created a demand for the rivastigmine drug for the treatment of these diseases.

 

The increasing death of neurons, known as neurodegeneration, destroys this vital organism over time and as these connections are disrupted or terminated due to multiple dead cells, patients experience cognitive impairment such as memory loss which worsens with age, they may also experience behavioral changes and mood swings. The Alzheimer’s drug control signals by restoring some lost function in cholinergic synapses a connection where one neuron sends a signal or pressure through an axon to the next neuron, which receives it from its dendrites. According to Alzheimer’s Disease International (ADI), in 2020, there are over 55 million people living with dementia across the globe. This number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050 and as much of the increase will be in developing countries. Already 60.0% of people with dementia live in low and middle-income countries, however, by 2050 this will rise to 71.0%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbors.

 

In addition, according to the Centers for Disease Control and Prevention, Alzheimer’s is one of the 10 leading causes of death in the US. The death toll from the disease has risen sharply in the US over the past few years. More than 122k mortalities occurredin the country due to Alzheimer’s disease in 2019. Most common among people aged 85 and over, about 5.7 million people are living with Alzheimer’s Disease in the US. Looking towards the high demand for drugs that can treat Alzheimer’s and Parkinson’s disease several healthcare providers are providing approval for the drugs that can be used for the treatment of such diseases.For instance, in June 2021, the US FDA has approved the first treatment of Alzheimer’s that is addressing the underlying pathology and the anti-amyloid antibody aducanumab of Biogen and Eisai, now called Aduhelm, this removes amyloid plaque from the brain. Approval of such medications is anticipated to drive the growth of the global rivastigmine market.

 

Market Coverage

 

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease Indication
  • By Formulation
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Allergan, Eisai Co., Ltd., Novartis AG, Daiichi SankyoCo., Ltd., Merz Pharma, Pfizer Inc., and Johnson & Johnson Services, Inc., among others.

 

Key questions addressed by the report

 

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Rivastigmine Market Report by Segment

 

By Disease Indication

• Alzheimer Disease
• Parkinson’s Disease

By Formulation

• Capsules
• Transdermal Patches

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 

Global Rivastigmine Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa